[The impact of platelet membrane autoantibodies on high-dose dexamethasone therapy in patients with idiopathic thrombocytopenic purpura].

Abstract

OBJECTIVE:

To evaluate the impact of platelet membrane glycoprotein (GP)-specific autoantibodies on high-dose dexamethasone therapy in patients with idiopathic thrombocytopenic purpura (ITP).

METHODS:

Modified direct monoclonal antibody immobilization of platelet antigen assay (MAIPA) was used to detect platelet GPIIb/IIIa and/or GPI b specific autoantibodies. All patients received oral dexamethasone 40 mg/d for 4 days.

RESULTS:

The response rate of high-dose dexamethasone in GPIIb/IIIa and/or GPIb specific autoantibody-negative patients was significantly different from that of antibody-positive patients (P<0.05). The response rate of GPIIb/IIIa specific autoantibody-positive patients was lower than that of antibody-negative patients (P<0.05). GPIb specific autoantibody had no significant impact on the efficacy of high-dose dexamethasone (P>0.05).

CONCLUSION:

Platelet membrane GPIIb/IIIa-specific autoantibody can be a potential negative indicator for ITP patients'response to high-dose oral dexamethasone.

• Authors: Rui Wang, Ping Qin, Xue-bin Ji, Ming Hou
• Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi (Zhonghua Xue Ye Xue Za Zhi) Vol. 30 Issue 9 Pg. 619-21 (Sep 2009) ISSN: 0253-2727 [Print] China
• PMID: 19954623 (Publication Type: English Abstract, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Autoantibodies
• Platelet Glycoprotein GPIIb-IIIa Complex
• Platelet Glycoprotein GPIb-IX Complex
• Dexamethasone

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Autoantibodies (blood)
• Dexamethasone (administration & dosage, therapeutic use)
• Female
• Humans
• Male
• Middle Aged
• Platelet Glycoprotein GPIIb-IIIa Complex (immunology)
• Platelet Glycoprotein GPIb-IX Complex (immunology)
• Purpura, Thrombocytopenic, Idiopathic (drug therapy, immunology)
• Treatment Outcome
• Young Adult